Cargando…
Dramatic response to alectinib in a patient with ALK‐rearranged squamous cell lung cancer
Lung cancers with anaplastic lymphoma kinase (ALK) rearrangements are highly sensitive to treatment with ALK tyrosine kinase inhibitors (TKIs). Due to the very low rate of patients with squamous cell carcinoma enrolled in clinical trials, the efficacy of ALK inhibitors in patients with ALK‐rearrange...
Autores principales: | Shiihara, Jun, Ohyanagi, Fumiyoshi, Amari, Hikari, Toda, Minemichi, Tahara, Hiroki, Yuzawa, Motoi, Maeda, Yuki, Nomura, Motoko, Mizushina, Yoshiko, Nagai, Yoshiaki, Ohta, Hiromitsu, Yamaguchi, Yasuhiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410551/ https://www.ncbi.nlm.nih.gov/pubmed/34324792 http://dx.doi.org/10.1111/1759-7714.14092 |
Ejemplares similares
-
Clinical case of lung spindle cell carcinoma markedly responsive to pembrolizumab
por: Mizushina, Yoshiko, et al.
Publicado: (2021) -
Immunoglobulin G4-related Pleuritis Complicated with Minimal Change Disease
por: Mizushina, Yoshiko, et al.
Publicado: (2021) -
Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status
por: Tanaka, Hisashi, et al.
Publicado: (2016) -
ALK-Positive Squamous Cell Carcinoma Dramatically Responded to Alectinib
por: Sagawa, Ray, et al.
Publicado: (2018) -
Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
por: Imanishi, Naoko, et al.
Publicado: (2018)